Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling

BACKGROUND: We previously showed that activation of the nuclear factor of activated T cells (NFAT)1/Fas ligand (FasL) pathway induces glioma cell death. Lithium (Li) is an inhibitor of glycogen synthase kinase (GSK)-3 that activates NFAT1/FasL signalling. Temozolomide (TMZ) inhibits GSK-3 and activa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Han, Sheng, Meng, Lingxuan, Jiang, Yang, Cheng, Wen, Tie, Xinxin, Xia, Junzhe, Wu, Anhua
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2017
Assuntos:
Translational Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482734/
https://ncbi.nlm.nih.gov/pubmed/28359080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.89
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares